Wedbush Downgrades Pharmacyclics (PCYC) to Neutral; Potential Takeover Mostly Priced In
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- US stock futures steady after tech slump; investors focus on Middle East tensions
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- U.S. debt tops $40 trillion
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Deutsche Bank calls Treasury buyback doubling similar to ’operation twist’
Goldman Sachs Downgrades Pharmacyclics (PCYC) to Neutral
February 27, 2015 6:32 AM ESTGoldman Sachs downgraded Pharmacyclics (NASDAQ: PCYC) from Buy to Neutral.
For an analyst ratings summary and ratings history on Pharmacyclics click here. For more ratings news on Pharmacyclics click here.
Shares of Pharmacyclics closed at $217.82 yesterday.
... MoreCredit Suisse Downgrades Pharmacyclics (PCYC) to Neutral
February 27, 2015 6:26 AM ESTCredit Suisse downgraded Pharmacyclics (NASDAQ: PCYC) from Outperform to Neutral with a price target of $233.00 (from $163.00) on valuation following the recent surge on takeover reports.
Analyst J. Kantor thinks the $17-18 billion target range discussed adequately reflects the value of the Imbruvica... More
